预约演示

更新于：2025-05-07

poliomyelitis due to poliovirus type I

脊髓灰质炎I型脊髓灰质炎

更新于：2025-05-07

基本信息

别名

poliomyelitis due to poliovirus type I、poliomyelitis due to poliovirus type I (diagnosis)

简介-

关联

项与脊髓灰质炎I型脊髓灰质炎相关的药物

Poliomyelitis (Live) Vaccine Type I Type III (Human Diploid Cell), Oral( Institute of Medical Biology Chinese Academy of Medical Sciences)

I型+III型口服脊髓灰质炎减毒活疫苗(人二倍体细胞)(中国医学科学院医学生物学研究所)

靶点-

作用机制

免疫刺激剂

在研机构

中国医学科学院医学生物学研究所

原研机构

中国医学科学院医学生物学研究所

在研适应症

脊髓灰质炎 [+2]

非在研适应症-

最高研发阶段批准上市

首次获批国家/地区

中国

首次获批日期2018-10-29

Poliovirus vaccine live oral bivalent (Panacea Biotec)

靶点-

作用机制

免疫刺激剂

在研机构

Panacea Biotec Ltd.

原研机构

Panacea Biotec Ltd.

在研适应症

脊髓灰质炎I型脊髓灰质炎 [+1]

非在研适应症-

最高研发阶段批准上市

首次获批国家/地区-

首次获批日期1800-01-20

monovalent oral polio vaccine type 1 (mOPV1) (Panacea Biotec)

靶点-

作用机制

免疫刺激剂

在研机构

Panacea Biotec Ltd.

原研机构

Panacea Biotec Ltd.

在研适应症

脊髓灰质炎I型脊髓灰质炎

非在研适应症-

最高研发阶段批准上市

首次获批国家/地区-

首次获批日期1800-01-20

项与脊髓灰质炎I型脊髓灰质炎相关的临床试验

CTR20160169

/ Active, not recruiting临床3期

随机、盲法、平行对照试验评价双价脊髓灰质炎减毒活疫苗（人二倍体细胞）与IPV联合序贯免疫临床试验

主要目标：比较2剂cIPV/sIPV+1剂tOPV（液体剂型/糖丸）与2剂cIPV/sIPV+1剂bOPV(液体剂型/糖丸)序贯接种后Ⅰ、Ⅱ、Ⅲ型脊髓灰质炎抗体阳转率和抗体水平。次要目标：（1）比较1剂cIPV/sIPV+2剂tOPV（液体剂型/糖丸）与2剂cIPV/sIPV+1剂bOPV(液体剂型/糖丸)序贯接种后Ⅰ、Ⅱ、Ⅲ型脊髓灰质炎抗体阳转率和抗体水平。（2）评价bOPV（液体剂型/糖丸）疫苗的安全性。

开始日期2015-09-15

申办/合作机构

中国医学科学院医学生物学研究所

CTR20160167

/ Active, not recruiting临床3期

随机、盲法、平行对照试验评价双价脊髓灰质炎减毒活疫苗（人二倍体细胞）与IPV联合序贯免疫临床试验

开始日期2015-09-15

申办/合作机构

中国医学科学院医学生物学研究所

100 项与脊髓灰质炎I型脊髓灰质炎相关的临床结果

登录后查看更多信息

100 项与脊髓灰质炎I型脊髓灰质炎相关的转化医学

登录后查看更多信息

0 项与脊髓灰质炎I型脊髓灰质炎相关的专利（医药）

登录后查看更多信息

项与脊髓灰质炎I型脊髓灰质炎相关的文献（医药）

1990-11-01·Cytotechnology4区 · 生物学

Growth of poliovirus using alginate entrapped-anchorage dependant Vero cells

4区 · 生物学

Article

作者: Robert Alain ; Pierre Trépanier ; Robert Dugré ; Jacques Lapierre

Obligatory anchorage dependant Vero cells were successfully grown in gelatinous-like macrocarriers made of calcium alginate. Entrapped single cells were immobilized within the polymerized alginate matrix divide to form large spherical clumps of cells. A cell density of 17 x 10(6) cells/ml of alginate with over 95% viability was obtained after 14 days in spinner flasks. When subjected to poliovirus type I infection, spherical masses of Vero cells progressively showed extensive cytopathic effect but remained entrapped in the alginate matrix of the macrocarriers. Virus was released into a cellular debris free-like supernatant and reached a peak titer of 10(8.0) TCID50/ml after 72 hours.

1974-02-01·Archives of Neurology

Acute Poliomyelitis Beginning as Transverse Myelopathy

Article

作者: Foley, K. M. ; Beresford, H. R.

A 16-year-old boy developed an acute neurological illness characterized by flaccid paraplegia, bladder dysfunction, and striking sensory disturbances in the lower extremities. A myelogram was normal, but there was a pleocytosis and increased content of protein in the cerebrospinal fluid. Serologic and epidemiologic studies indicated a type I poliovirus infection. He had never received polio vaccine. Although previous reviews have stressed its rarity, this patient is described as an additional example of prominent sensory loss in acute poliomyelitis.

1972-12-01·East African medical journal

Outbreak of type I paralytic poliomyelitis in Kampala City and the surrounding Mengo (East and West Buganda) Districts of Uganda during 1969.

Article

作者: Munube, G M